RU2002113750A - Производные пиррола в качестве ингибиторов фосфодиэстеразы VII - Google Patents
Производные пиррола в качестве ингибиторов фосфодиэстеразы VIIInfo
- Publication number
- RU2002113750A RU2002113750A RU2002113750/15A RU2002113750A RU2002113750A RU 2002113750 A RU2002113750 A RU 2002113750A RU 2002113750/15 A RU2002113750/15 A RU 2002113750/15A RU 2002113750 A RU2002113750 A RU 2002113750A RU 2002113750 A RU2002113750 A RU 2002113750A
- Authority
- RU
- Russia
- Prior art keywords
- solvates
- formula
- acceptable salts
- physiologically acceptable
- phosphodiesterase vii
- Prior art date
Links
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 title claims 3
- 150000003233 pyrroles Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
Claims (3)
1. Соединения формулы I
в которой R1, R2 независимо друг от друга каждый обозначает Н, А, ОА, SA или Hal,
R3 обозначает Н или А,
R4 обозначает А или NH2,
R5 обозначает Н, NH2, NHA или NA2,
А обозначает алкил, имеющий от 1 до 10 атомов С, алкенил, циклоалкил или алкиленциклоалкил, Hal обозначает F, C1, Br или I,
а также их физиологически приемлемые соли и/или сольваты в качестве ингибиторов фосфодиэстеразы VII.
2. Фармацевтический препарат, отличающийся тем, что содержит по меньшей мере один ингибитор фосфодиэстеразы VII формулы I по п.1 и/или одну из его физиологически приемлемых солей и/или один из его сольватов.
3. Применение соединений формулы I по п.1 и/или их физиологически приемлемых солей или сольватов для получения лекарственного препарата для борьбы с аллергическими заболеваниями, астмой, хроническим бронхитом, атопическим дерматитом, псориазом и другими кожными заболеваниями, воспалительными заболеваниями, автоиммунными заболеваниями, такими как, например, ревматоидный артрит, рассеянным склерозом, болезнью Крона, сахарным диабетом или язвенным колитом, остеопорозом, реакцией отторжения трансплантатов, кахексией, ростом опухолей или метастаз опухолей, сепсисом, нарушениями памяти, атеросклерозом и СПИДом.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19953025.4 | 1999-11-04 | ||
| DE19953025A DE19953025A1 (de) | 1999-11-04 | 1999-11-04 | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002113750A true RU2002113750A (ru) | 2004-01-10 |
Family
ID=7927861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002113750/15A RU2002113750A (ru) | 1999-11-04 | 2000-10-25 | Производные пиррола в качестве ингибиторов фосфодиэстеразы VII |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6737436B1 (ru) |
| EP (1) | EP1230215B1 (ru) |
| JP (1) | JP2003513070A (ru) |
| KR (1) | KR20020063173A (ru) |
| CN (1) | CN1382122A (ru) |
| AR (1) | AR026351A1 (ru) |
| AT (1) | ATE339403T1 (ru) |
| AU (1) | AU782477B2 (ru) |
| BR (1) | BR0015334A (ru) |
| CA (1) | CA2389709C (ru) |
| CZ (1) | CZ20021440A3 (ru) |
| DE (2) | DE19953025A1 (ru) |
| ES (1) | ES2272331T3 (ru) |
| HK (1) | HK1049831A1 (ru) |
| HU (1) | HUP0203288A3 (ru) |
| MX (1) | MXPA02004440A (ru) |
| NO (1) | NO20022125L (ru) |
| PL (1) | PL355099A1 (ru) |
| RU (1) | RU2002113750A (ru) |
| SK (1) | SK5952002A3 (ru) |
| WO (1) | WO2001032618A1 (ru) |
| ZA (1) | ZA200204433B (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6946481B1 (en) * | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| DE60222931T2 (de) | 2001-12-13 | 2008-07-10 | Asubio Pharma Co., Ltd. | Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung |
| DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| DE10226420A1 (de) * | 2002-06-13 | 2004-01-15 | Eucro European Contract Research Gmbh & Co Kg | Verfahren zur Behandlung der Artherosklerose |
| JP2006219373A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| PL1775298T3 (pl) | 2004-07-01 | 2013-08-30 | Daiichi Sankyo Co Ltd | Pochodna tienopirazolowa wykazująca aktywność hamowania PDE7 |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| EP2139475B1 (en) | 2007-03-27 | 2014-12-17 | Omeros Corporation | PDE7 inhibitors for use in the treatment of movement disorders |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20120115849A1 (en) | 2010-11-08 | 2012-05-10 | Demopulos Gregory A | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| JP7213863B2 (ja) | 2017-07-12 | 2023-01-27 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ７阻害剤としての置換ベンゾオキサゾール及びベンゾフラン化合物 |
| EP4572765A1 (en) | 2022-08-18 | 2025-06-25 | Mitodicure GmbH | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE154827C (ru) | ||||
| DD154827A1 (de) * | 1980-11-28 | 1982-04-21 | Karl Gewald | Verfahren zur herstellung von azofarbstoffen aus substituierten 3-aminopyrrolen |
| PT946507E (pt) * | 1996-12-10 | 2004-02-27 | Searle & Co | Compostos de pirrolilo substituidos para o tratamento da inflamacao |
-
1999
- 1999-11-04 DE DE19953025A patent/DE19953025A1/de not_active Withdrawn
-
2000
- 2000-10-25 MX MXPA02004440A patent/MXPA02004440A/es unknown
- 2000-10-25 BR BR0015334-6A patent/BR0015334A/pt not_active Application Discontinuation
- 2000-10-25 CA CA002389709A patent/CA2389709C/en not_active Expired - Fee Related
- 2000-10-25 HK HK03101865.7A patent/HK1049831A1/zh unknown
- 2000-10-25 RU RU2002113750/15A patent/RU2002113750A/ru unknown
- 2000-10-25 DE DE50013473T patent/DE50013473D1/de not_active Expired - Lifetime
- 2000-10-25 AU AU13873/01A patent/AU782477B2/en not_active Ceased
- 2000-10-25 AT AT00975917T patent/ATE339403T1/de not_active IP Right Cessation
- 2000-10-25 WO PCT/EP2000/010526 patent/WO2001032618A1/de not_active Ceased
- 2000-10-25 EP EP00975917A patent/EP1230215B1/de not_active Expired - Lifetime
- 2000-10-25 SK SK595-2002A patent/SK5952002A3/sk unknown
- 2000-10-25 PL PL00355099A patent/PL355099A1/xx unknown
- 2000-10-25 HU HU0203288A patent/HUP0203288A3/hu unknown
- 2000-10-25 US US10/129,261 patent/US6737436B1/en not_active Expired - Fee Related
- 2000-10-25 JP JP2001534770A patent/JP2003513070A/ja active Pending
- 2000-10-25 KR KR1020027005646A patent/KR20020063173A/ko not_active Withdrawn
- 2000-10-25 ES ES00975917T patent/ES2272331T3/es not_active Expired - Lifetime
- 2000-10-25 CN CN00814828A patent/CN1382122A/zh active Pending
- 2000-10-25 CZ CZ20021440A patent/CZ20021440A3/cs unknown
- 2000-11-03 AR ARP000105800A patent/AR026351A1/es unknown
-
2002
- 2002-05-03 NO NO20022125A patent/NO20022125L/no not_active Application Discontinuation
- 2002-06-03 ZA ZA200204433A patent/ZA200204433B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0203288A2 (hu) | 2003-01-28 |
| WO2001032618A1 (de) | 2001-05-10 |
| CN1382122A (zh) | 2002-11-27 |
| JP2003513070A (ja) | 2003-04-08 |
| ATE339403T1 (de) | 2006-10-15 |
| AU782477B2 (en) | 2005-08-04 |
| CA2389709A1 (en) | 2001-05-10 |
| DE19953025A1 (de) | 2001-05-10 |
| AR026351A1 (es) | 2003-02-05 |
| AU1387301A (en) | 2001-05-14 |
| EP1230215B1 (de) | 2006-09-13 |
| BR0015334A (pt) | 2002-07-09 |
| NO20022125D0 (no) | 2002-05-03 |
| EP1230215A1 (de) | 2002-08-14 |
| HK1049831A1 (zh) | 2003-05-30 |
| CZ20021440A3 (cs) | 2002-07-17 |
| CA2389709C (en) | 2009-02-10 |
| DE50013473D1 (de) | 2006-10-26 |
| MXPA02004440A (es) | 2004-09-10 |
| SK5952002A3 (en) | 2002-09-10 |
| US6737436B1 (en) | 2004-05-18 |
| NO20022125L (no) | 2002-05-03 |
| ZA200204433B (en) | 2003-09-03 |
| HUP0203288A3 (en) | 2003-12-29 |
| KR20020063173A (ko) | 2002-08-01 |
| ES2272331T3 (es) | 2007-05-01 |
| PL355099A1 (en) | 2004-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002113750A (ru) | Производные пиррола в качестве ингибиторов фосфодиэстеразы VII | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| ES2461967T3 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| RU2002113759A (ru) | Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII | |
| PL181694B1 (pl) | Pochodne cyjanidowe PL PL PL | |
| CA2429979A1 (en) | Treatment of statin side effects | |
| RU2002113746A (ru) | Производные изоксазола в качестве ингибиторов фосфодиэстеразы VII | |
| RU2008123839A (ru) | Соединение оксазола и фармацевтическая композиция | |
| JP2007137903A (ja) | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸の塩 | |
| CA2481926A1 (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by .alpha.4 integrins | |
| JP2006518728A5 (ru) | ||
| WO1982003859A1 (fr) | Derives de 1-sulfo-2-oxoazetidine et procede de preparation | |
| RU2001122164A (ru) | Кристаллическая кальциевая соль бис[(е)-7-[4-(4-фторфенил)-6-изопропил-2-[метил(метилсульфонил)амино]- пиримидин-5-ил]-(3r,5s)-3,5-дигидроксигепт-6-еновой кислоты] | |
| SI3106463T1 (en) | Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase | |
| JP2014514322A (ja) | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 | |
| RU2002128004A (ru) | Содержащие гетероциклическую боковую цепь ингибиторы металлопротеиназы | |
| JP2010006817A (ja) | 炎症性障害を治療する化合物 | |
| RU2006111354A (ru) | Кристаллическая форма кальциевой соли бис-[(e)-7-[4-(4-фторфенил)-6-изопропил-2-[метил(метилсульфонил]-пиримин-5-ил](3r, 5s)-3, 5-дигидроксигепт-6-еновой кислоты | |
| JP2010522710A (ja) | Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体 | |
| JP2024020453A (ja) | Ｒｏｃｋ阻害剤としての重水素化合物 | |
| WO2023283453A1 (en) | Phenyl acetamide based il-17a modulators and uses thereof | |
| RU2006133373A (ru) | Производные имидазолина, обладающие св1-антагонистической активностью | |
| RU2004137115A (ru) | Пентафторсульфанилбензоилгуанидины, способ их получения, их применение в качестве лекарственных или диагностических средств, а также получение лекарственного средства | |
| JP2024522718A (ja) | 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物 | |
| RU2002111413A (ru) | Производные имидазола в качестве ингибиторов фосфодиэстеразы VII |